본문 바로가기
KERD
논문KCI 등재

Systemic Chemotherapy in Advanced Pancreatic Cancer

박승우|Hee Seung Lee
거트앤리버 소화기연관학회협의회|2016.05|Gut and Liver|제10권 제3호|pp. 340-347

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

Drug therapyPancreatic neoplasmsGemcitabineFluorouracil

초록

Pancreatic cancer remains one of the most lethal cancers. These patients often have multiple symptoms, and integrated supportive care is critical in helping them remain well for as long as possible. Fluorouracil-based chemotherapy is known to improve overall survival (OS) by approximately 3 months, compared to the best supportive care alone. A 1997 study comparing gemcitabine and fluorouracil treatment of advanced pancreatic cancer patients showed an improvement in OS of 1 month in patients receiving gemcitabine. Over the next 10 years, multiple randomized studies compared singleagent gemcitabine with combination chemotherapy and showed no effective survival improvement. However, the addition of erlotinib, an epidermal growth factor receptor (EGFR) inhibitor, was associated with a significant improvement in OS of approximately 2 weeks. However, adoption of this regimen has not been widespread because of its limited effect and added toxicity. Two clinical trials have recently prolonged OS in advanced pancreatic cancer patients by almost 1 year. The first compared FOLFIRINOX with gemcitabine alone, and was associated with a significant improvement in median survival. The second compared gemcitabine and nabpaclitaxel with gemcitabine alone, and was associated with improvements in OS. At present, these regimens are considered standard treatment for patients with good performance statuses.

Abstract

Pancreatic cancer remains one of the most lethal cancers. These patients often have multiple symptoms, and integrated supportive care is critical in helping them remain well for as long as possible. Fluorouracil-based chemotherapy is known to improve overall survival (OS) by approximately 3 months, compared to the best supportive care alone. A 1997 study comparing gemcitabine and fluorouracil treatment of advanced pancreatic cancer patients showed an improvement in OS of 1 month in patients receiving gemcitabine. Over the next 10 years, multiple randomized studies compared singleagent gemcitabine with combination chemotherapy and showed no effective survival improvement. However, the addition of erlotinib, an epidermal growth factor receptor (EGFR) inhibitor, was associated with a significant improvement in OS of approximately 2 weeks. However, adoption of this regimen has not been widespread because of its limited effect and added toxicity. Two clinical trials have recently prolonged OS in advanced pancreatic cancer patients by almost 1 year. The first compared FOLFIRINOX with gemcitabine alone, and was associated with a significant improvement in median survival. The second compared gemcitabine and nabpaclitaxel with gemcitabine alone, and was associated with improvements in OS. At present, these regimens are considered standard treatment for patients with good performance statuses.

참고문헌 (51)

  1. Ryan DP, "Pancreatic adenocarcinoma", N Engl J Med, 371, pp.1039~1049 (2014)
  2. "National cancer registration program" (2012)[URL]
  3. Conroy T, "FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer", N Engl J Med, 364, pp.1817~1825 (2011)
  4. Ko AH, "Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities", J Clin Oncol, 33, pp.1779~1786 (2015)
  5. DeCaprio JA, "Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial", J Clin Oncol, 9, pp.2128~2133 (1991)
  6. Van Rijswijk RE, "Weekly high-dose 5-fluorouracil and folinic acid in metastatic pancreatic carcinoma:a phase II study of the EORTC GastroIntestinal Tract Cancer Cooperative Group", Eur J Cancer, 40, pp.2077~2081 (2004)
  7. Schüller J, "Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients", Cancer Chemother Pharmacol, 45, pp.291~297 (2000)
  8. Cartwright TH, "Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer", J Clin Oncol, 20, pp.160~164 (2002)
  9. Ueno H, "Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study", J Clin Oncol, 31, pp.1640~1648 (2013)
  10. Cullinan SA, "A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin", JAMA, 253, pp.2061~2067 (1985)
  11. Cullinan S, "A phase III trial on the therapy of advanced pancreatic carcinoma: evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin", Cancer, 65, pp.2207~2212 (1990)
  12. Burris HA 3rd, "Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial", J Clin Oncol, 15, pp.2403~2413 (1997)
  13. Berlin JD, "Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297", J Clin Oncol, 20, pp.3270~3275 (2002)
  14. Herrmann R, "Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group", J Clin Oncol, 25, pp.2212~2217 (2007)
  15. Cunningham D, "Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer", J Clin Oncol, 27, pp.5513~5518 (2009)
  16. Heinemann V, "Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer", J Clin Oncol, 24, pp.3946~3952 (2006)
  17. Colucci G, "Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study", J Clin Oncol, 28, pp.1645~1651 (2010)
  18. Chao Y, "A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer", Cancer Chemother Pharmacol, 72, pp.637~642 (2013)
  19. Ferrone CR, "BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma", J Clin Oncol, 27, pp.433~438 (2009)
  20. Stathopoulos GP, "A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer", Br J Cancer, 95, pp.587~592 (2006)
  21. Reni M, "Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomized controlled multicentre phase III trial", Lancet Oncol, 6, pp.369~376 (2005)
  22. Louvet C, "Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial", J Clin Oncol, 23, pp.3509~3516 (2005)
  23. Poplin E, "Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group", J Clin Oncol, 27, pp.3778~3785 (2009)
  24. Moore MJ, "Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group", J Clin Oncol, 25, pp.1960~1966 (2007)
  25. Michl P, "Current concepts and novel targets in advanced pancreatic cancer", Gut, 62, pp.317~326 (2013)
  26. Androulakis N, "Treatment of pancreatic cancer with docetaxel and granulocyte colonystimulating factor: a multicenter phase II study", J Clin Oncol, 17, pp.1779~1785 (1999)
  27. Wagener DJ, "Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study", Ann Oncol, 6, pp.129~132 (1995)
  28. Stevenson JP, "Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas", Eur J Cancer, 34, pp.1358~1362 (1998)
  29. Von Hoff DD, "Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine", N Engl J Med, 369, pp.1691~1703 (2013)
  30. Infante JR, "Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma", J Clin Oncol, 25, pp.319~325 (2007)
  31. Xiong HQ, "Phase 2 trial of oxaliplatin plus capecitabine (XELOX)as second-line therapy for patients with advanced pancreatic cancer", Cancer, 113, pp.2046~2052 (2008)
  32. Pelzer U, "Best supportive care (BSC)versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group", Eur J Cancer, 47, pp.1676~1681 (2011)
  33. Heinemann V, "Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104)", Gut, 62, pp.751~759 (2013)
  34. di Magliano MP, "Roles for KRAS in pancreatic tumor development and progression", Gastroenterology, 144, pp.1220~1229 (2013)
  35. Bryant KL, "KRAS: feeding pancreatic cancer proliferation", Trends Biochem Sci, 39, pp.91~100 (2014)
  36. Van Cutsem E, "Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer", J Clin Oncol, 22, pp.1430~1438 (2004)
  37. Kindler HL, "Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)", J Clin Oncol, 28, pp.3617~3622 (2010)
  38. Kindler HL, "Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium", Invest New Drugs, 30, pp.382~386 (2012)
  39. O’Reilly EM, "A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603)", Oncologist, 15, pp.1310~1319 (2010)
  40. Van Cutsem E, "Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer", J Clin Oncol, 27, pp.2231~2237 (2009)
  41. Philip PA, "Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205", J Clin Oncol, 28, pp.3605~3610 (2010)
  42. Olive KP, "Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer", Science, 324, pp.1457~1461 (2009)
  43. Hilbig A, "Transforming growth factor beta in pancreatic cancer", Curr Pharm Biotechnol, 12, pp.2158~2164 (2011)
  44. Fuxe J, "TGF-beta-induced epithelial-mesenchymal transition: a link between cancer and inflammation", Semin Cancer Biol, 22, pp.455~461 (2012)
  45. Jacobetz MA, "Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer", Gut, 62, pp.112~120 (2013)
  46. Vanneman M, "Combining immunotherapy and targeted therapies in cancer treatment", Nat Rev Cancer, 12, pp.237~251 (2012)
  47. Dodson LF, "Potential targets for pancreatic cancer immunotherapeutics", Immunotherapy, 3, pp.517~537 (2011)
  48. Beatty GL, "CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans", Science, 331, pp.1612~1616 (2011)
  49. Vasef MA, "Telomerase activity in human solid tumors: diagnostic utility and clinical applications", Am J Clin Pathol, 112(1 Suppl 1), pp.S68~S75 (1999)
  50. Middleton G, "Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial", Lancet Oncol, 15, pp.829~840 (2014)
  51. 박세미, "Phase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Response", Gut and Liver, 7(5), pp.611~615 (2013), 거트앤리버 발행위원회

관련 논문AI추천

Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer윤동섭, 이동기, 이세준, 임재윤, 조장호, 조재용대한암학회 · Cancer Research and Treatment2015 · 제47권 제2호The Molecular Targets for the Diagnosis and Treatment of Pancreatic CancerAlexios S. Strimpakos, Kostas N. Syrigos, Muhammad Wasif Saif거트앤리버 소화기연관학회협의회 · Gut and Liver2010 · 제4권 제4호Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial김경하, 김세형, 김찬규, 김한조, 문종호, 박성규, 배상병, 윤진아, 이규택, 이남수, 이민영, 이상철, 이윤나, 임성희연세대학교의과대학 · Yonsei Medical Journal2021 · 제62권 제8호Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy김용태, 류지곤, 손준혁, 이상협, 이재우, 장동기, 청광현거트앤리버 소화기연관학회협의회 · Gut and Liver2017 · 제11권 제2호The clinical outcomes of second-line chemotherapy in patients with advanced pancreatic cancer: a retrospective study정현엽, Eun Mi Lee영남대학교 의과대학 · Journal of Yeungnam Medical Science2022 · 제39권 제2호A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer김준석, 서재홍, 오상철, 최종권, 최철원대한암학회 · Cancer Research and Treatment2012 · 제44권 제2호

이 간행물의 다른 논문 (25건)

The Garlic Preparation as an Alternative Way for Gastroprotection: From Bench to ClinicJong-Jae Parkpp. 321-322Helicobacter pylori Eradication, a Gordian Knot for Idiopathic Thrombocytopenic Purpura?김태호, 정대영pp. 323-324Mast Cell May Be the Master Key to Solve the Mystery of Pathogenesis of Irritable Bowel SyndromeHyuk Yoonpp. 325-326Patients’ Preference for a Specific Anti-Tumor Necrosis Factor Agent: Korea versus WesternHyungil Seo, Byong Duk Yepp. 327-329The Mental Health State of Quiescent Inflammatory Bowel Disease PatientsYoon Tae Jeen, Sung Chul Parkpp. 330-331
원문 보기